

Godelieve A M Tytgat

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9313125/publications.pdf>

Version: 2024-02-01

42
papers

1,416
citations

471509

17
h-index

345221

36
g-index

42
all docs

42
docs citations

42
times ranked

2352
citing authors

#	ARTICLE	IF	CITATIONS
1	TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors. <i>Nature Genetics</i> , 2015, 47, 1411-1414.	21.4	313
2	An organoid biobank for childhood kidney cancers that captures disease and tissue heterogeneity. <i>Nature Communications</i> , 2020, 11, 1310.	12.8	183
3	Gain of 1q As a Prognostic Biomarker in Wilms Tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 3195-3203.	1.6	105
4	Recommendations for the standardization of bone marrow disease assessment and reporting in children with neuroblastoma on behalf of the International Neuroblastoma Response Criteria Bone Marrow Working Group. <i>Cancer</i> , 2017, 123, 1095-1105.	4.1	75
5	Detecting Minimal Residual Disease in Neuroblastoma: The Superiority of a Panel of Real-Time Quantitative PCR Markers. <i>Clinical Chemistry</i> , 2009, 55, 1316-1326.	3.2	65
6	Catecholamines profiles at diagnosis: Increased diagnostic sensitivity and correlation with biological and clinical features in neuroblastoma patients. <i>European Journal of Cancer</i> , 2017, 72, 235-243.	2.8	57
7	The pitfalls and promise of liquid biopsies for diagnosing and treating solid tumors in children: a review. <i>European Journal of Pediatrics</i> , 2020, 179, 191-202.	2.7	55
8	Fenretinide induces mitochondrial ROS and inhibits the mitochondrial respiratory chain in neuroblastoma. <i>Cellular and Molecular Life Sciences</i> , 2010, 67, 807-816.	5.4	51
9	The prognostic value of fast molecular response of marrow disease in patients aged over 1year with stage 4 neuroblastoma. <i>European Journal of Cancer</i> , 2011, 47, 1193-1202.	2.8	41
10	Differentiated Thyroid Carcinoma After 131I-MIBG Treatment for Neuroblastoma During Childhood: Description of the First Two Cases. <i>Thyroid</i> , 2012, 22, 643-646.	4.5	32
11	Nuclear Medicine Imaging in Neuroblastoma: Current Status and New Developments. <i>Journal of Personalized Medicine</i> , 2021, 11, 270.	2.5	31
12	Methylated RASSF1a Is the First Specific DNA Marker for Minimal Residual Disease Testing in Neuroblastoma. <i>Clinical Cancer Research</i> , 2012, 18, 808-814.	7.0	30
13	Characteristics and Outcome of Children with Renal Cell Carcinoma: A Narrative Review. <i>Cancers</i> , 2020, 12, 1776.	3.7	29
14	Feasibility, toxicity and response of upfront metaiodobenzylguanidine therapy followed by German Pediatric Oncology Group Neuroblastoma 2004 protocol in newly diagnosed stage 4 neuroblastoma patients. <i>European Journal of Cancer</i> , 2017, 76, 188-196.	2.8	28
15	Mesenchymal Stromal Cells in Neuroblastoma: Exploring Crosstalk and Therapeutic Implications. <i>Stem Cells and Development</i> , 2021, 30, 59-78.	2.1	25
16	Organoid-based drug screening reveals neddylation as therapeutic target for malignant rhabdoid tumors. <i>Cell Reports</i> , 2021, 36, 109568.	6.4	25
17	Minimally invasive classification of paediatric solid tumours using reduced representation bisulphite sequencing of cell-free DNA: a proof-of-principle study. <i>Epigenetics</i> , 2021, 16, 196-208.	2.7	23
18	Whole-Genome Sequencing Identifies Patient-Specific DNA Minimal Residual Disease Markers in Neuroblastoma. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 43-52.	2.8	19

#	ARTICLE	IF	CITATIONS
19	Combining Hypermethylated RASSF1A Detection Using ddPCR with miR-371a-3p Testing: An Improved Panel of Liquid Biopsy Biomarkers for Testicular Germ Cell Tumor Patients. <i>Cancers</i> , 2021, 13, 5228.	3.7	18
20	Mesenchymal Neuroblastoma Cells Are Undetected by Current mRNA Marker Panels: The Development of a Specific Neuroblastoma Mesenchymal Minimal Residual Disease Panel. <i>JCO Precision Oncology</i> , 2019, 3, 1-11.	3.0	17
21	Catecholamine excretion profiles identify clinical subgroups of neuroblastoma patients. <i>European Journal of Cancer</i> , 2019, 111, 21-29.	2.8	17
22	The feasibility of using liquid biopsies as a complementary assay for copy number aberration profiling in routinely collected paediatric cancer patient samples. <i>European Journal of Cancer</i> , 2022, 160, 12-23.	2.8	16
23	3-Methoxytyramine: An independent prognostic biomarker that associates with high-risk disease and poor clinical outcome in neuroblastoma patients. <i>European Journal of Cancer</i> , 2018, 90, 102-110.	2.8	15
24	CD47-SIRP α Checkpoint Inhibition Enhances Neutrophil-Mediated Killing of Dinutuximab-Opsonized Neuroblastoma Cells. <i>Cancers</i> , 2021, 13, 4261.	3.7	15
25	The Metastatic Bone Marrow Niche in Neuroblastoma: Altered Phenotype and Function of Mesenchymal Stromal Cells. <i>Cancers</i> , 2020, 12, 3231.	3.7	14
26	Hypermethylated <i>RASSF1A</i> as Circulating Tumor DNA Marker for Disease Monitoring in Neuroblastoma. <i>JCO Precision Oncology</i> , 2020, 4, 291-306.	3.0	14
27	Specific and Sensitive Detection of Neuroblastoma mRNA Markers by Multiplex RT-qPCR. <i>Cancers</i> , 2021, 13, 150.	3.7	13
28	Improving Risk Stratification for Pediatric Patients with Rhabdomyosarcoma by Molecular Detection of Disseminated Disease. <i>Clinical Cancer Research</i> , 2021, 27, 5576-5585.	7.0	13
29	Novel Circulating Hypermethylated RASSF1A ddPCR for Liquid Biopsies in Patients With Pediatric Solid Tumors. <i>JCO Precision Oncology</i> , 2021, 5, 1738-1748.	3.0	13
30	Neuroblastoma messenger RNA is frequently detected in bone marrow at diagnosis of localised neuroblastoma patients. <i>European Journal of Cancer</i> , 2016, 54, 149-158.	2.8	10
31	Human megakaryocytes cultured in vitro accumulate serotonin but not meta-iodobenzylguanidine whereas platelets concentrate both. <i>Experimental Hematology</i> , 2002, 30, 555-563.	0.4	9
32	Meta-iodobenzylguanidine uptake in platelets, megakaryoblastic leukaemia cell lines MKPL-1 and CHRf-288-11 and erythroleukaemic cell line HEL. <i>European Journal of Cancer</i> , 1995, 31, 603-606.	2.8	8
33	Peripheral Stem Cell Apheresis is Feasible Post ¹³¹ Iodine-Metaiodobenzylguanidine-Therapy in High-Risk Neuroblastoma, but Results in Delayed Platelet Reconstitution. <i>Clinical Cancer Research</i> , 2019, 25, 1012-1021.	7.0	7
34	The Potential of Mesenchymal Stromal Cells in Neuroblastoma Therapy for Delivery of Anti-Cancer Agents and Hematopoietic Recovery. <i>Journal of Personalized Medicine</i> , 2021, 11, 161.	2.5	6
35	Bilateral Renal Tumors in Children: The First 5 Years [™] Experience of National Centralization in The Netherlands and a Narrative Review of the Literature. <i>Journal of Clinical Medicine</i> , 2021, 10, 5558.	2.4	6
36	Selective serotonin reuptake inhibitors (SSRIs) prevent meta-iodobenzylguanidine (MIBG) uptake in platelets without affecting neuroblastoma tumor uptake. <i>EJNMMI Research</i> , 2020, 10, 78.	2.5	5

#	ARTICLE	IF	CITATIONS
37	Urinary 3-Methoxytyramine Is a Biomarker for MYC Activity in Patients With Neuroblastoma. <i>JCO Precision Oncology</i> , 2022, 6, e2000447.	3.0	4
38	Characteristics and Outcome of Children with Wilms Tumor Requiring Intensive Care Admission in First Line Therapy. <i>Cancers</i> , 2022, 14, 943.	3.7	4
39	Extracellular Vesicles: A New Source of Biomarkers in Pediatric Solid Tumors? A Systematic Review. <i>Frontiers in Oncology</i> , 2022, 12, .	2.8	3
40	Thrombocytopenia after meta-iodobenzylguanidine (MIBG) therapy in neuroblastoma patients may be caused by selective MIBG uptake via the serotonin transporter located on megakaryocytes. <i>EJNMMI Research</i> , 2021, 11, 81.	2.5	1
41	Anti-GD2 Based Immunotherapy Prevents Late Events in High-Risk Neuroblastoma Patients over 18 Months at Diagnosis. <i>Cancers</i> , 2021, 13, 4941.	3.7	1
42	A Common Genomic Denominator for Neuroblastoma and Differentiated Thyroid Carcinoma? A Case Series in Children. <i>Clinical Oncology</i> , 2022, , .	1.4	0